Your browser doesn't support javascript.
loading
Targeting circRNA-MAP4K2 for the treatment of diabetes-induced retinal vascular dysfunction.
Ma, Cong; Shi, Ze-Hui; Han, Xiao-Yan; Liu, Chang; Yan, Biao; Du, Jian-Ling.
Afiliação
  • Ma C; Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
  • Shi ZH; Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
  • Han XY; Eye Institute, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Liu C; Eye Institute, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Yan B; Eye Institute, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Du JL; Eye Institute, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Aging (Albany NY) ; 14(15): 6255-6268, 2022 Aug 11.
Article em En | MEDLINE | ID: mdl-35963645
Diabetic retinopathy (DR) is an important ocular vascular disease in working-age adults. However, the molecular mechanism underlying retinal vascular dysfunction is still not fully understood in DR. Circular RNAs have been recognized as the crucial regulators in many biological processes and human diseases. Herein, we determined the role of circular RNA-MAP4K2 (cMAP4K2) in diabetes-induced retinal vascular dysfunction. The results showed that high glucose treatment led to increased levels of cMAP4K2 expression in vitro and in vivo. Silencing of cMAP4K2 could reduce endothelial cell viability, proliferation, migration, and tube formation in vitro and alleviate retinal vascular dysfunction in vivo as shown by decreased vascular leakage and inflammation. By contrast, cMAP4K2 overexpression had an opposite effect on retinal vascular dysfunction. Mechanistically, cMAP4K2 acted as miR-377 sponge to affect the biological activity of miR-377, which led to increased expression of vascular endothelial growth factor A (VEGFA). Clinically, cMAP4K2 expression was significantly up-regulated in the clinical sample of DR patients. Collectively, cMAP4K2 is shown as a potential target for the diagnosis and treatment of diabetic retinopathy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Diabetes Mellitus / Retinopatia Diabética / Quinases do Centro Germinativo Limite: Humans Idioma: En Revista: Aging (Albany NY) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Diabetes Mellitus / Retinopatia Diabética / Quinases do Centro Germinativo Limite: Humans Idioma: En Revista: Aging (Albany NY) Ano de publicação: 2022 Tipo de documento: Article